Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 5
Submit an article Journal homepage
341
Views
7
CrossRef citations to date
0
Altmetric
Drug Profiles

Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia

Ali T TaherDepartment of Internal Medicine, American University of Beirut, Riad El Solh 1107 2020, Beirut, LebanonCorrespondence[email protected]
,
Sally TemrazDepartment of Internal Medicine, American University of Beirut, Riad El Solh 1107 2020, Beirut, Lebanon
&
M Domenica CappelliniUniversità di Milano, Ca Granda Foundation IRCCS, Milan, Italy
Pages 495-509 | Published online: 10 Jan 2014

References

  • Cao A, Galanello R. Beta-thalassemia. Genet. Med. 12, 61–76 (2010).
  • Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet. J. Rare. Dis. 5, 13 (2010).
  • Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 80, 339–344 (2009).
  • Vichinsky E. Advances in the treatment of alpha-thalassemia. Blood Rev. 26 (Suppl. 1), S31–S34 (2012).
  • Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 26 (Suppl. 1), S7–S11 (2012).
  • Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 26 (Suppl. 1), S3–S6 (2012).
  • Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 80, 58–68 (1995).
  • Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemias and hemoglobin E disorders. Expert Rev. Hematol. 3, 103–117 (2010).
  • Michlitsch J, Azimi M, Hoppe C et al. Newborn screening for hemoglobinopathies in California. Pediatr. Blood Cancer 52, 486–490 (2009).
  • Vichinsky E. Hemoglobin E syndromes. Hematology Am. Soc. Hematol. Educ. Program 79–83 (2007).
  • Vichinsky EP. Changing patterns of thalassemia worldwide. Ann. N. Y. Acad. Sci. 1054, 18–24 (2005).
  • Lal A, Goldrich ML, Haines DA et al. Heterogeneity of hemoglobin H disease in childhood. N. Engl. J. Med. 364, 710–718 (2011).
  • Laosombat V, Viprakasit V, Chotsampancharoen T et al. Clinical features and molecular analysis in Thai patients with HbH disease. Ann. Hematol. 88, 1185–1192 (2009).
  • Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: A clinical perspective. Cold Spring Harb. Perspect. Med. 2, a013482 (2012).
  • Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 79, 704–712 (2001).
  • Galanello R, Origa R. Beta-thalassemia. Orphanet. J. Rare. Dis. 5, 11 (2010).
  • Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β-thalassaemia intermedia. Br. J. Haematol. 152, 512–523 (2011).
  • Chen FE, Ooi C, Ha SY et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N. Engl. J. Med. 343, 544–550 (2000).
  • Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol. Dis. 37, 12–20 (2006).
  • Taher AT, Musallam KM, Karimi M et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 115, 1886–1892 (2010).
  • Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 26 (Suppl. 1), S16–S19 (2012).
  • Mallat NS, Mallat SG, Musallam KM, and Taher AT. Potential mechanisms for renal damage in beta-thalassemia. J. Nephrol. doi: 10.5301/jn.5000253 (2013) ( Epub ahead of print).
  • Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br. J. Haematol. 147, 634–640 (2009).
  • Musallam KM, Cappellini M.D., Wood JC et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β-thalassemia intermedia. Haematologica 96, 1605–1612 (2011).
  • Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 26 (Suppl. 1), S12–S15 (2012).
  • Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am. J. Hematol. 85, 288–290 (2010).
  • Au WY, Lam WW, Chu WW et al. Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease. Ann. Hematol. 88, 947–950 (2009).
  • Voskaridou E, Douskou M, Terpos E et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br. J. Haematol. 126, 736–742 (2004).
  • Lombardo T, Tamburino C, Bartoloni G et al. Cardiac iron overload in thalassemic patients: an endomyocardial biopsy study. Ann. Hematol. 71, 135–141 (1995).
  • Glickstein H, El BR, Link G et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108, 3195–3203 (2006).
  • Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5 mg/g liver iron concentration threshold and its association with vascular and endocrine/bone morbidity in β-thalassemia intermedia. Blood 120(21), abstract 1024 (2012).
  • Musallam KM, Cappellini MD, Daar S et al. Serum ferritin levels and morbidity in β-thalassemia intermedia: A 10-year cohort study. Blood 120(21), abstract 1021 (2012).
  • Taher AT, Musallam KM, El-Beshlawy A et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br. J. Haematol. 150, 486–489 (2010).
  • Taher AT, Porter J, Viprakasit V et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 120, 970–977 (2012).
  • Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am. J. Hematol. 88, 409–415 (2013).
  • Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am. Soc. Hematol. Educ. Program 215–221 (2009).
  • Origa R, Galanello R, Ganz T et al. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92, 583–588 (2007).
  • Pakbaz Z, Fischer R, Fung E et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr. Blood Cancer 49, 329–332 (2007).
  • Taher A, El Rassi F, Isma'eel H et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 93, 1584–1586 (2008).
  • Taher AT, Porter JB, Viprakasit V et al. Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-dependent thalassemia patients: Analysis from the 1-year THALASSA study. Haematologica 97 (Suppl. 1), abstract 0927 (2012).
  • Wood JC. Magnetic resonance imaging measurement of iron overload. Curr. Opin. Hematol. 14, 183–190 (2007).
  • Gandon Y, Olivie D, Guyader D et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363, 357–362 (2004).
  • St Pierre TG, Clark PR, Chua-anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105, 855–861 (2005).
  • Hankins JS, McCarville MB, Loeffler RB et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 113, 4853–4855 (2009).
  • Garbowski MW, Carpenter J-P, Smith G, Pennell DJ, and Porter JB. Calibration of improved T2* method for the estimation of liver iron concentration in transfusional iron overload. Blood 114(22), abstract 2004 (2009).
  • St Pierre TG, El-Beshlawy A, Elalfy MS et al. Multicenter validation of spin-density projection-assisted R2-MRI for the non-invasive measurement of liver iron concentration. Blood 116(21), abstract 2053 (2010).
  • Heli H, Mirtorabi S, Karimian K. Advances in iron chelation: an update. Expert Opin. Ther. Pat. 21, 819–856 (2011).
  • Ma Y, Zhou T, Kong X, Hider RC. Chelating agents for the treatment of systemic iron overload. Curr. Med. Chem. 19, 2816–2827 (2012).
  • Delea TE, Sofrygin O, Thomas SK et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients. US healthcare system perspective. Pharmacoeconomics 25, 329–342 (2007).
  • Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 47, 1919–1929 (2007).
  • Cappellini MD, Pattoneri P. Oral iron chelators. Annu. Rev. Med. 60, 25–38 (2009).
  • Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. Hemoglobin 30, 229–238 (2006).
  • Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 32, 41–47 (2008).
  • Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin 32, 49–62 (2008).
  • Cossu P, Toccafondi C, Vardeu F et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur. J. Pediatr. 137, 267–271 (1981).
  • Olivieri NF, Koren G, Matsui D et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79, 2741–2748 (1992).
  • Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in β-thalassemia intermedia. Birth Defects Orig. Artic. Ser. 23, 29–33 (1988).
  • Pootrakul P, Sirankapracha P, Sankote J et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br. J. Haematol. 122, 305–310 (2003).
  • Rombos Y, Tzanetea R, Konstantopoulos K et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 85, 115–117 (2000).
  • Akrawinthawong K, Chaowalit N, Chatuparisuth T, Siritanaratkul N. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology 16, 113–122 (2011).
  • Chan JC, Chim C-S, Ooi CG et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br. J Haematol. 133, 198–205 (2006).
  • Neufeld EJ, Galanello R, Viprakasit V et al. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 119, 3263–3268 (2012).
  • Rienhoff HY, Jr., Viprakasit V, Tay L et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 96, 521–525 (2011).
  • Galanello R, Aydinok Y, Piga A et al. A 48 week phase 2 study of the safety, tolerability and efficacy of FBS0701, a novel iron chelator for treatment of transfusional iron overload. Haematologica 97 (Suppl. 1), abstract 0606 (2012).
  • Aydinok Y, Galanello R, Viprakasit V et al. The safety, tolerability and efficacy of fbs0701, an iron chelator in clinical development for transfusional iron overload: data from 72 weeks of treatment. Haematologica 98 (Suppl. 1), abstract S1175 (2013).
  • El Ouagari K, Migliaccio-Walle K, Lau H, Bozkaya D. Cost-effectiveness of deferasirox in lower-risk myelodysplastic syndrome (MDS) in Canada (abstract 343). Leuk Res. 35, S137-S138 (2011).
  • Calabro A, Delea TE, Sofrygin O et al. Cost-effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassemic patients: a Brazilian perspective. Haematologica 91(Suppl. 1), abstract 804 (2006).
  • Delea TE, Thomas SK, Baladi J, Phatak PD. Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade®, ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic syndrome. Blood 106(11), abstract 5585 (2005).
  • Galanello R, Campus S, Origa R. Deferasirox : pharmacokinetics and clinical experience. Expert Opin. Drug Metab. Toxicol. 8, 123–134 (2012).
  • Steinhauser S, Heinz U, Bartholoma M et al. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur. J. Inorg. Chem. 21, 4177–4192 (2004).
  • Bruin GJ, Faller T, Wiegand H et al. Pharmacokinetics, distribution, metabolism and excretion of deferasirox and its iron complex in rats. Drug Metab. Dispos. 36, 2523–2538 (2008).
  • Piga A, Galanello R, Forni GL et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91, 873–880 (2006).
  • Waldmeier F, Bruin GJ, Glaenzel U et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab. Dispos. 38, 808–816 (2010).
  • Skerjanec A, Wang J, Maren K, Rojkjaer L. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J. Clin. Pharmacol. 50, 205–213 (2010).
  • Ladis V, Berdousi H, Gotsis E, and Kattamis A. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br. J. Haematol. 151, 504–508 (2010).
  • Voskaridou E, Plata E, Douskou M et al. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br. J. Haematol. 148, 332–334 (2010).
  • Taher AT, Porter JB, Viprakasit V et al. Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox: Results from the 1-year THALASSA study. Haematologica 97 (Suppl. 1), abstract 0924 (2012).
  • Taher AT, Porter JB, Viprakasit V et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann. Hematol doi:10.1007/s00277-013-1808-z (2013) (Epub ahead of print).
  • Taher AT, Porter JB, Viprakasit V et al. Deferasirox continues to reduce iron overload in non-transfusion-dependent thalassemia: A one-year, open-label extension to a one-year, randomized, double-blind, placebo-controlled study (THALASSA). Blood 120(21), abstract 3258 (2012).
  • Voskaridou E, Plata E, Douskou M et al. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/beta-thalassemia. Ann. Hematol. 90, 11–15 (2011).
  • Taher A, Cappellini MD, Vichinsky E et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br. J. Haematol. 147, 752–759 (2009).
  • Vichinsky E. Clinical application of deferasirox: Practical patient management. Am. J. Hematol. 83, 398–402 (2008).
  • Taher A, Porter J, Viprakasit V et al. The safety profile of deferasirox remains consistent as non-transfusion-dependent thalassemia patients approach the target liver iron concentration of <3 mg Fe/g dw for interrupting chelation. Haematologica. 98 (Suppl. 1), abstract P391 (2013).
  • Cappellini MD, Porter JB, El-Beshlawy A et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 95, 557–566 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.